MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Harrow Health Cash Conversion Cycle 2011-2026 | HROW
Annual Cash Conversion Cycle Harrow Health
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -86.6 | -65.5 | -28.6 | 20.6 | -70 | -80.2 | -22.1 | -9.54 | -108 | -120 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.6 | -120 | -57.1 |
Quarterly Cash Conversion Cycle Harrow Health
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.2 | 4.08 | 24.5 | - | -28.1 | -6.01 | -15.4 | - | -33.1 | -43.1 | -46.3 | - | -60.6 | -20 | -12.7 | - | -24.3 | -11.2 | -17.3 | - | -2.14 | 8.21 | -64.6 | - | -102 | -77.3 | -113 | - | -97.3 | -97.7 | -74.5 | - | -43.8 | -47.2 | 14.6 | - | 5.16 | 4.26 | 3.75 | - | 6.12 | 8.35 | 5.37 | - | 0.83 | 0.55 | 91.2 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 91.2 | -113 | -22.5 |
Cash Conversion Cycle of other stocks in the Drug manufacturers industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-128 | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-224 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
460 | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
177 | $ 1.27 | 6.72 % | $ 137 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-58.9 | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
213 | $ 2.67 | -0.19 % | $ 1.41 B | Canada |
 |
Agile Therapeutics
AGRX
|
-206 | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
110 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
41.4 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
139 | - | -39.89 % | $ 27.7 M | USA |
 |
HEXO Corp.
HEXO
|
775 | - | 2.45 % | $ 38.1 M | Canada |
 |
Endo International plc
ENDP
|
141 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
45.7 | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
181 | $ 13.99 | 0.58 % | $ 716 M | USA |
 |
Athenex
ATNX
|
137 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
192 | $ 21.43 | -0.33 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
74.6 | $ 5.66 | 0.03 % | $ 351 M | USA |
 |
China Pharma Holdings
CPHI
|
164 | $ 1.58 | 17.04 % | $ 27.6 M |  China |
 |
Jupiter Wellness
JUPW
|
-21.1 | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
2.92 K | $ 1.72 | 2.08 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
78.9 | $ 7.89 | -0.25 % | $ 2.88 B | Canada |
 |
Pacira BioSciences
PCRX
|
209 | $ 26.1 | 0.38 % | $ 1.21 B | USA |
 |
Lannett Company
LCI
|
173 | - | 1.15 % | $ 7.11 M | USA |
 |
Rockwell Medical
RMTI
|
45 | $ 0.98 | 3.51 % | $ 22.9 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-161 | $ 4.88 | -5.97 % | $ 68.6 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
150 | $ 3.78 | 0.27 % | $ 4.69 M | USA |
 |
Organogenesis Holdings
ORGO
|
64.5 | $ 4.26 | -0.81 % | $ 561 M | USA |
 |
Aurora Cannabis
ACB
|
1.45 K | $ 4.29 | 1.06 % | $ 86.3 M | Canada |
 |
PetIQ
PETQ
|
53.8 | - | 1.64 % | $ 400 M | USA |
 |
Veru
VERU
|
6.7 | $ 2.31 | -2.53 % | $ 312 M | USA |
 |
Recro Pharma
REPH
|
105 | - | -4.76 % | $ 65.3 M | USA |
 |
Perrigo Company plc
PRGO
|
138 | $ 14.83 | 1.61 % | $ 2.04 B | USA |
 |
ProPhase Labs
PRPH
|
96 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-53.5 | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
92 | $ 1.06 | -4.93 % | $ 4.57 M | USA |
 |
OptiNose
OPTN
|
314 | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
327 | $ 9.42 | -0.11 % | $ 669 M | USA |
 |
PLx Pharma
PLXP
|
111 | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
106 | $ 0.65 | 1.26 % | $ 31.1 M | USA |
 |
Tilray
TLRY
|
169 | $ 9.12 | 1.39 % | $ 5.64 B | Canada |
 |
TherapeuticsMD
TXMD
|
-723 | $ 2.01 | -1.47 % | $ 21 M | USA |
 |
Viatris
VTRS
|
155 | $ 12.53 | 0.52 % | $ 15.2 B | USA |
 |
Zomedica Corp.
ZOM
|
196 | - | -0.21 % | $ 98 M | USA |